Sanofi's Nexviadyme gets EU approval in Pompe disease

Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval

AbbVie announces CHMP recommendation for approval of upadacitinib (RINVOQ) to treat active non-radiographic axial spondyloarthritis in adults

Ipsen agrees to acquire Epizyme

ImmuPharma reports Avion seeking final FDA guidance ahead of Phase 3 trial of Lupuzor

BioMarin Pharmaceutical's valoctocogene roxaparvovec recommended for conditional marketing authorisation by European regulator

Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial

Investigational Lenacapavir Receives Positive CHMP Opinion for People with Multi-Drug Resistant HIV

US FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

Merck gets EU approval for KEYTRUDA as adjuvant treatment of patients with resected stage IIB or IIC melanoma

CNS Pharmaceuticals receives FDA approval for global study assessing Berubicin's efficacy and safety

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Purdue Pharma Introduces Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) in the US for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids

US FDA Approves Merck's Vaxneuvance for the Prevention of Invasive Pneumococcal Disease in Infants and Children

ANI Pharmaceuticals Receives FDA Approval of, Plans Imminent Launch of Clorazepate Dipotassium Tablets USP